{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002781","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.761969+00:00","generated_at":"2026-05-22T13:24:16.628053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025","bullets":["Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.","Q1 2025 net income $43.1M (basic EPS $5.12); diluted net loss per share ($2.11) due to warrant fair value change.","Phase 2 B-SUPREME study of ALG-000184 in chronic HBV expected to begin mid-2025; interim data 2026, topline 2027.","ALG-055009 (THR-β agonist) Phase 2a HERALD showed placebo-adjusted median liver fat reduction up to 46.2%; up to 70% subjects achieved ≥30% reduction.","ALG-097558 pan-coronavirus inhibitor has 3 clinical trials ongoing; NIAID study Q2 2025. Company seeking external funding for further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002781","json":"https://secwatch.observer/filing/0001171843-25-002781.json","markdown":"https://secwatch.observer/filing/0001171843-25-002781.md","text":"https://secwatch.observer/filing/0001171843-25-002781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325002781/0001171843-25-002781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325002781/f8k_050525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:24:16.628053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}